Form 4: Castle Biosciences COO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Castle Biosciences' Chief Operating Officer, Kristen M. Oelschlager, sold 12,677 shares of common stock for $22.019 per share under a pre-arranged Rule 10b5-1 plan.
Summary
- Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences Inc. (CSTL), sold 12,677 shares of common stock.
- The sale occurred on August 27, 2025, at a weighted-average price of $22.019 per share.
- The transaction was executed pursuant to a Rule 10b5-1 plan adopted on March 6, 2025.
- Following the transaction, Ms. Oelschlager directly beneficially owns 141,116 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral. The transaction is a pre-planned insider sale under a 10b5-1 plan, which is a routine event for executive compensation and personal financial management, not indicative of new company-specific news.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating a scheduled transaction rather than a reaction to new, non-public information.
Negatives
- An insider sale, even if pre-planned, reduces the officer's direct equity stake in the company.
Future Outlook
NA
Industry Context
This is an individual insider transaction and does not directly relate to broader industry trends or competitors, other than reflecting an officer's personal financial planning.
Stakeholder Impact
- Shareholders: A minor reduction in insider ownership, but mitigated by the 10b5-1 plan. The sale itself is small relative to the company's market capitalization and the officer's remaining holdings.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date Rule 10b5-1 plan was adopted by the Reporting Person. |
| 08/27/2025 | Date of transaction (sale of common stock). |
| 08/29/2025 | Date the Form 4 was signed/filed. |
Recommendation
holdThe filing details a routine, pre-planned insider sale under a 10b5-1 plan. Such transactions are generally not indicative of new material information about the company's performance or prospects and therefore do not warrant a change in investment recommendation based solely on this filing. It represents a personal financial management event for the executive.
Keywords
Castle Biosciences, CSTL, Insider Sale, Form 4, Kristen M Oelschlager, Chief Operating Officer, 10b5-1 Plan, Equity Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.